Express News | QuantaSing Announces Changes in Composition of Board
Bank of America Securities: Reiterates ALI HEALTH (00241) "Buy" rating with a Target Price of 4.6 Hong Kong dollars.
The management of ALI HEALTH is also confident about the revenue and adjusted net profit targets for the fiscal years 2025 and 2026.
In 2024, Hong Kong stocks: The Hang Seng Index reached a new high in nearly four years, and the net Inflow of southbound funds exceeded 700 billion.
① How does the overall trend of the Hong Kong stock market perform in 2024? ② What role does southbound capital play in the Hong Kong stock market in 2024? ③ What is the perspective of Institutions for 2025?
ALI HEALTH: FISCAL YEAR 2025 INTERIM REPORT
[Brokerage Focus] UBS Group raises target price for Ali Health (00241) by 13.6%, reflecting the company's renewed emphasis on prescription drugs and pursuit of market share.
Golden Giraffe Financial News | UBS Group released research reports indicating that ali health (00241) management reiterated its goal of revenue growth of 10% or more for the fiscal year 2025, with adjusted net profit exceeding 2 billion yuan; the revenue target for the fiscal year 2026 is also to increase by 10% or more, with adjusted net profit ranging from 2.3 billion yuan to 2.5 billion yuan. Starting from the second half of fiscal year 2025, revenue growth will be driven by the accelerated growth of prescription drugs and the continuous growth of over-the-counter drugs. The bank believes that the company's renewed emphasis on prescription drugs reflects the pursuit of market share, or may be a condition to maintain the current level of gross margin. Based on weak consumer spending, the bank has lowered its revenue forecast for over-the-counter drugs.
[Brokerage Focus] Haitong Int'l cuts Ali Health (00241) target price by 14.5% as the company's first-half fiscal year sales fall below expectations.
Jingwu Financial News | Haitong Int'l issued a research report stating that Ali Health (00241) released its interim results for the six months ending September 30, 2024. As of FY25H1, the company achieved revenue of 14.27 billion yuan (+10.2%), gross profit of 3.53 billion yuan (+23.2%), net income of 0.77 billion yuan (+72.8%), and adjusted net income of 0.98 billion yuan (+52.2%); corresponding to a gross margin of 24.8% (+2.6pct), net margin of 5.4% (+2.0pct), and adjusted net margin of 6.8% (+1.9pct). The company's gross margin and net.
103677010 : noted